Nutriset's Plumpy'Nut: a 30-cent peanut paste that replaced hospital feeding

Before ready-to-use therapeutic food, rehabilitating a severely malnourished child meant a hospital bed, therapeutic milk, clean water and refrigeration — infrastructure that famine zones lack by definition. Powdered feeds had to be mixed with water before consumption, as Nutriset's own patent dryly notes, which made them a hazard wherever the water was unsafe. Children relapsed between clinic visits, and the feeding centers themselves became the bottleneck in every emergency.

In 1997 the French pediatrician André Briend published the idea of a solid 'therapeutic spread', and Nutriset, a family firm in Malaunay, France, turned it into a patented product. US Patent 6346284 (granted 2002) claims a complete food containing at most 10% water, with low osmolality and oxidative stability — a full nutrient dose in a peanut-based paste. Plumpy'Nut needs no water, no preparation and no refrigeration, and keeps for two years in a packet about the size of a candy bag.

The clinical evidence followed. Mark Manary ran the first Plumpy'Nut trial in 2001; a 2004 Journal of Pediatric Gastroenterology and Nutrition study enrolled 260 severely malnourished Malawian children, gave each family packets for home use after a brief stabilization, and 78% reached full catch-up growth — with locally produced paste matching the imported kind (80% vs 75% recovery). NPR reports the product costs roughly 30 cents a packet and that by Manary's estimate about 40 million children have been treated since 2001, with recovery rates of 80–90%.

Scale followed the design. RUTF use rose from about 5 million children a year in the early 2020s to 9 million in 2024. Edesia Nutrition, founded in Rhode Island to industrialize the US supply, makes Plumpy'Nut for around 5 million children across 30 countries in a typical year. The patents' expiry — the US one in 2017, the European equivalent in 2018 — left behind a distributed manufacturing base rather than a monopoly.

A shelf-stable paste mothers can feed at home.

Removing water kills the cold chain: under 10% moisture means no bacterial growth, no mixing with contaminated wells and a two-year shelf life in foil.

Home delivery removes the hospital bottleneck — the mother becomes the care system, so coverage scales with packet supply instead of bed capacity.

Commodity ingredients (peanut paste, milk powder, oil, sugar, vitamins) let production move to peanut-growing regions; the 2004 trial proved local packets were as effective as imported ones.

The patent gave Nutriset the confidence to invest in industrial quality control for a customer base of aid agencies, then expire into a commodity market.

A fixed 730 kJ/kg/day ration is simple enough for fortnightly follow-up visits rather than inpatient care.

Redesign the delivery system, not just the product: care that moves from institution to household multiplies reach without new clinics. Let the patent expire into distributed manufacturing.

Ready-to-use therapeutic food became the global standard for severe acute malnutrition. Production decentralized from France across Africa, the Americas and Asia; Edesia in Rhode Island alone produced for 5 million children in 30 countries in a typical year. The franchise proved fragile to politics rather than science: 2025 US aid disruptions put stop-work orders on Edesia, and UNICEF warned that funding cuts could leave 2.4 million children without access to RUTF.